Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include: 

• Evidence from the monarchE and NATALEE trials of adjuvant abemaciclib and ribociclib, respectively in HR+/HER2- high-risk early breast cancer
• Factors used to assess risk of recurrence in early breast cancer, including the role of Ki-67 expression
• Determining the need for adjuvant chemotherapy and selection of chemotherapy agents
• Selection of patients who may benefit from the addition of adjuvant CDK4/6 inhibitor therapy with endocrine therapy
• Potential use of preoperative CDK4/6 inhibitors
• Sequencing therapy for patients with high-risk early breast cancer and a germline BRCA mutation
• Overview of first-line therapy for advanced HR+/HER2 breast cancer
• Expert opinion on selection of first-line therapy and factors to consider
• Selection of second-line therapy based on mutational analysis and recent data from the post-MONARCH trial

Presenters:
Joyce O’Shaughnessy, MD
Celebrating Women Chair in 
Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas

Sara A. Hurvitz, MD, FACP
Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

Erica L. Mayer, MD, MPH
Director of Breast Cancer Clinical Research
Institute Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Link to full program: 
https://bit.ly/3XZKp8f

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.